Meet Our Supporters

Session supported by Helsinn

Meet the Experts: Optimizing Antiemetic Prophylaxis for New Anticancer Agents: A Comprehensive Approach in Accordance with International Guidelines

Panelists:

• Prof Grazia Arpino (Italy)
• Prof Florian Scotté (France)

Session Description: Interactive discussion between an ADC breast cancer expert and a CINV expert based on a clinical case that will also involve the audience. The objective is to clarify some important aspects around the CINV management with the new anticancer agents, specifically the ADC (antibody drug conjugates), according to the recently updated MASCC ESMO guidelines.

This session is supported by Biocon Biologics

From Acute to Long-Term Safety: How to Manage Emerging Treatments

Agenda:

• Introduction – Prof Florian Scotté (France)
• Neutropenia Related to Immune Checkpoint Inhibitors – Dr Tim Cooksley (United Kingdom)
• Neutropenia: Are We Correctly Using GCSF? – Prof Mahasti Saghatchian (France)
• Long-Term Safety and Monoclonal Antibodies: What Do We Have to Know? – Prof Hope Rugo (USA)
• Panel discussion to follow

Session Description: The session will provide a comprehensive overview of neutropenia management, encompassing current practices as well as advancements in anticancer treatments. It will delve into the challenges posed by Long-Term Toxicity, particularly in light of the increased survival rates associated with monoclonal antibody therapies. This emerging survivorship area will prompt important discussions on navigating the complexities of long-term care and quality of life for cancer survivors.

This session is supported by Daiichi-Sankyo / AstraZeneca

Striking a Balance: Optimising the Patient Experience in HER2-low Metastatic Breast Cancer

Agenda:

• Introduction by Session Chair – Prof Hope Rugo (USA)
• Clinical Trial Developments in HER2-low Breast Cancer – Dr Véronique Diéras (France)
• Optimising Treatment Outcomes Through Toxicity Management – Dr Rita Nanda (USA)
• What Comes First? The Considerations for Sequencing in Breast Cancer – Prof Hope Rugo (USA)
• Panel discussion to follow

Session Description: This session will highlight the importance of managing adverse events through multidisciplinary teamwork, review the recent clinical trial data in HER2-low metastatic breast cancer and discuss treatment sequencing to optimise the patient experience in HER2-low metastatic breast cancer.

This session is supported by Daiichi-Sankyo / AstraZeneca

Bridging the Gap: Developing Care for Patients Receiving Antibody-Drug Conjugates 

Agenda:

• Introduction – Prof Florian Scotté, Session Chair (France)
• Laying the Foundations: The Role of ADCs in Metastatic Breast Cancer – Prof Daniele Santini (Italy)
• Constructing Management Strategies for GI Disorders in Patients Receiving ADCs – Prof Matti Aapro (Switzerland)
• Crossing the Divide: Translating Guideline Recommendations to Real-World Patient Care – Prof Grazia Arpino (Italy)
• Panel discussion to follow

Session Description: Interactive session exploring the risk-benefit profile of ADCs in metastatic breast cancer including discussions on common treatment effects and how they can be managed in real-world clinical practice.

Session sponsored by Chugai

Neutropenic Events Associated with New Anticancer Treatments: From Pathophysiology to Practice

Agenda:

• Introduction by Session Co-Chairs: Prof Lodovico Balducci (USA), Prof Claire Falandry (France)
• PARP and CDK Inhibitors – Dr Gabriel Antherieu (France)
• Immunotherapy – Dr Vincent Thibaud (France)
• CAR T-cells – Dr Pierre Sesques (France)
• Panel discussion to follow

Session supported by Pharmanovia

Meet the Experts: Severe Diarrhea in Oncology

Session Chair: Prof Florian Scotté

• Diarrhea Prevention and Management: From the Studies to the Guidelines – Dr Paolo Bossi (Italy)
• Interactive Clinical Case – Prof Florian Scotté (France)

Session Description: The management of the severe diarrhea in patients with cancer from the etiology and assessment to the practical guidelines 

LEO Pharma-sponsored session

Meet the Experts: Challenging Clinical Scenario in Frail CAT Patients

Panelists:

• Prof Florian Scotté (France)
• Dr Didier Mayeur (France)

Session Description: 

• To shed light on the tailored management of vulnerable patients with CAT for whom the benefit-risk ratio of anticoagulant therapy may be modified.
• To provide advice to optimize anticoagulant treatment and to decide anticoagulant of choice in these clinical scenarios.

This session is supported by Eli Lilly and Co.

Get Ready, Get Set, Prehabilitate! Current Approaches to Lifestyle-Based Prehabilitation Before Cancer Treatment.

Session Chairs: Prof Raymond Chan (Australia), Assoc Prof Nicolas Hart (Australia)

Invited Speakers:

• The State of Science in Multimodal, Multidisciplinary Prehabilitation: What’s Next? – Dr Matthew Wallen (Australia)
• Effects of Multimodal Prehabilitation in Lung Cancer Setting: What’s the Trick? – Dr Francis-Edouard Gravier (France)

Oral Proffered Papers:

• Barriers To And Facilitators Of Access, Acceeptability And Adherence To Cancer Prehabilitation: A Mixed-Methods Systematic Review – Dr Tessa Watts (United Kingdom)
• Implementation Of A Prehabilitation Model Of Care Using Co-Designed Resources For Head And Neck Cancer Patients Prior To Radiotherapy – Ms Jenelle Loeliger (Australia)
• Effectiveness Of Prehabilitation In Patients With Breast Cancer Undergoing Neoadjuvant Therapy: Results From A Randomized Controlled Trial – Dr Raquel Sebio-Garcia (Spain)
• Feasibility Of A Trimodal Prehabilitation Program For Patients With Localized Pancreatic Cancer: A Multidisciplinary Approach – Dr Ana Ruiz Casado (Spain)

Session supported by La Roche-Posay

Optimization of Therapeutic Outcomes for Oncology Patients Through Appropriate Skin Care: ISKIMO Expert Consensus

Session Chair: Dr Mario Lacouture (USA)

• Skin Toxicities in Patients Under Oncology Drugs: An Overview – Dr Julie Ryan Wolf (USA)
• How Can DC Improve Patient Outcome? Clinical Study Results – Dr Delphine Kerob (France)
• The Role of Dermocosmetics in the Management of Cancer-Related Skin Toxicities: ISKIMO Expert Consensus – Prof Brigitte Dréno (France)
• A Patient Perspective – Lawrence Stallings
• Panel discussion to follow

Session Description: Skin toxicities are very common in patients undergoing cancer treatment and have been found to occur with all types of cancer therapeutic interventions. During this symposium, our speakers will provide general recommendations for initiation and selection of skin care in all oncology patients as well as recommendations for what factors should be considered when using dermocosmetics in specific types of skin toxicities.

Session sponsored by Thermo Fisher Scientific

Meet the Experts: Cancer Patients with New Fever – What Should I Do? Interactive Case-Based Discussion on Management – From the ED to the ICU

Panelist: Dr Stephen Pastores (USA)

Questions for Discussion:

• How to evaluate a new fever in a cancer patient in the Emergency Department?
• How to predict a serious bacterial infection and the need for ICU supportive modalities?
• How to optimize the duration of antimicrobial therapy using clinical data and biomarkers?

Session Description: In this interactive session, you will explore and discuss a comprehensive case study to learn how to effectively optimize the management of cancer patients presenting with a new fever.

Short Talk supported by Cureety

Short Talk: Real-World Deployment of Remote Patient Monitoring in Oncology Care Centers in France and Italy: Retrospective Analysis and Impact on Care Organisation

Speaker: Charles Parnot (France)

Session supported by Nestlé Health Science.

Optimising Nutrition in Oncology: Multidisciplinary Approaches to Enhance Patient Outcomes

Agenda:

• Nutritional Foundations in Cancer Care – Prof Diana Cardenas (France)
• A Roadmap for Nutritional Management in Oncology Care – Prof Paula Ravasco (Portugal)
• Panel discussion to follow

Session Description: The symposium aims to emphasize the critical role of nutrition in the cancer patient journey, detailing how adverse events affect nutritional status and the overall impact on clinical outcomes. It will also explore the role of the multidisciplinary team in managing these challenges through screening, nutritional interventions, and following established guidelines.